Didemnosides A and B: Antiproliferative Nucleosides from the Red Sea Marine Tunicate Didemnum Species
Marine Drugs · 2025
DOI: 10.3390/md23070262 ↗Kurz gefasst
Fachartikel in der Zeitschrift Marine Drugs, 2025. Verfasst von Lamiaa A Shaala und 7 weiteren Autor:innen. Beteiligte Einrichtung: Suez Canal University Hospitals, Suez Canal University, Ismailia 41522, Egypt. Hauptthemen laut MEDLINE: Urochordata, Antineoplastic Agents, Nucleosides. Die Arbeit nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Institutional Fund Project, Ministry of Education and King Abdulaziz University, DSR, Jeddah, Saudi Arabia, Institutional Fund Projects.
Abstract (Originalsprache)
Marine tunicates are a very attractive and abundant source of secondary metabolites with chemical diversity and biological activity. Fractionation and purification of the organic extract of the Red Sea tunicate Didemnum species resulted in the isolation and identification of three new compounds, didemnosides A and B (1 and 2) and 1,1′,3,3′-bisuracil (3), together with thymidine (4), 2′-deoxyuridine (5), homarine (6), and acetamide (7). Planar structures of the compounds were explained through analyses of their 1D (1H and 13C) and 2D (1H–1H COSY, HSQC, and HMBC) NMR spectra and high-resolution mass spectral determinations. Compound 1 exhibited the highest growth inhibition toward the MCF-7 cancer cell line with IC50 values of 0.597 μM, while other compounds were inactive (≥50 μM) against this cell line. On the other hand, compounds 1, 2, and 4–7 moderately inhibited SW-1222 and PC-3 cells with IC50 values ranging between 5.25 and 9.36 μM. Molecular docking analyses of the top three active compounds on each tested cell line exposed stable interactions into the active pockets of estrogen receptor alpha (ESR1), human topoisomerase II alpha (TOP2A), and cyclin-dependent kinase 5 (CDK5) which are contemplated as essential targets in cancer treatments. Thus, compound 1 represents a scaffold for the development of more effective anticancer drugs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Suez Canal University Hospitals, Suez Canal University, Ismailia 41522, Egypt.
- Department of Natural Products, Faculty of Pharmacy, King Abdulaziz University, Jeddah 21589, Saudi Arabia.
- King Fahd Medical Research Center, King Abdulaziz University, Jeddah 21589, Saudi Arabia.
- Department of Pharmacognosy, College of Pharmacy, Taif University, Al-Haweiah 21974, Saudi Arabia.
- Department of Pharmacy Practice, Faculty of Pharmacy, King Abdulaziz University, Jeddah 21589, Saudi Arabia.
- Vaccines and Immunotherapy Unit, King Fahd Medical Research Center, King Abdulaziz University, Jeddah 21589, Saudi Arabia.
ORCID-Profile: Diaa T A Youssef, Wafaa T Arab, Torki Alzughaibi, Noor M Bataweel
Förderung
- Institutional Fund Project, Ministry of Education and King Abdulaziz University, DSR, Jeddah, Saudi Arabia
- Institutional Fund Projects
Zitieren
APA
Shaala, L. A., Youssef, D. T. A., Almagthali, H., Almohammadi, A. M., Arab, W. T., Alzughaibi, T., Bataweel, N. M., & Ibrahim, R. S. (2025). Didemnosides A and B: Antiproliferative Nucleosides from the Red Sea Marine Tunicate Didemnum Species. Marine Drugs. https://doi.org/10.3390/md23070262
Vancouver
Shaala LA, Youssef DTA, Almagthali H, Almohammadi AM, Arab WT, Alzughaibi T, et al. Didemnosides A and B: Antiproliferative Nucleosides from the Red Sea Marine Tunicate Didemnum Species. Marine Drugs. 2025. doi:10.3390/md23070262
BibTeX
@article{Shaala2025,
author = {Shaala, Lamiaa A and Youssef, Diaa T A and Almagthali, Hadeel and Almohammadi, Ameen M and Arab, Wafaa T and Alzughaibi, Torki and Bataweel, Noor M and Ibrahim, Reham S},
title = {Didemnosides A and B: Antiproliferative Nucleosides from the Red Sea Marine Tunicate Didemnum Species},
journal = {Marine Drugs},
year = {2025},
doi = {10.3390/md23070262}
}
EUVIMED